Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia 1

Interventions

Azacitidine 23fludarabine phosphate 17Cyclophosphamide 16Decitabine 12Cytarabine 11Peripheral Blood Stem Cell Transplantation 10Whole-Body Irradiation 9Mycophenolic Acid 9Filgrastim 8Tacrolimus 7Cyclosporine 7venetoclax 6decitabine and cedazuridine drug combination 6fludarabine 5Carboplatin 5sargramostim 4Vorinostat 4Specimen Handling 4Sirolimus 4Radiotherapy 4Injections 4Cyclosporins 4Clofarabine 4Busulfan 4ruxolitinib 3cedazuridine 3aldesleukin 3Topotecan 3Melphalan 3Leucovorin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Myelomonocytic, Chronic × orludodstat × Clear all
NCT03404726 2022-01-11

A Study to Investigate BAY2402234, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Myeloid Malignancies

Bayer

Phase 1 Terminated
40 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡